These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 29194852)

  • 1. The role of sclerostin/dickkopf-1 and receptor activator of nuclear factor kB ligand/osteoprotegerin signalling pathways in the development of osteoporosis in patients with haemophilia A and B: A cross-sectional study.
    Anagnostis P; Vakalopoulou S; Christoulas D; Paschou SA; Papatheodorou A; Garipidou V; Kokkoris P; Terpos E
    Haemophilia; 2018 Mar; 24(2):316-322. PubMed ID: 29194852
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The key role of proinflammatory cytokines, matrix proteins, RANKL/OPG and Wnt/β-catenin in bone healing of hip arthroplasty patients.
    Cassuto J; Folestad A; Göthlin J; Malchau H; Kärrholm J
    Bone; 2018 Feb; 107():66-77. PubMed ID: 29129760
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Osteoprotegrin interacts with biomarkers and cytokines that have roles in osteoporosis, skin fibrosis, and vasculopathy in systemic sclerosis: A potential multifaceted relationship between OPG/RANKL/TRAIL and Wnt inhibitors.
    Taylan A; Birlik M; Kenar G; Toprak B; Gundogdu B; Gurler O; Karakas B; Akıncı B; Sisman AR
    Mod Rheumatol; 2019 Jul; 29(4):619-624. PubMed ID: 30001654
    [No Abstract]   [Full Text] [Related]  

  • 4. RANKL/OPG ratio and DKK-1 expression in primary osteoblastic cultures from osteoarthritic and osteoporotic subjects.
    Corrado A; Neve A; Macchiarola A; Gaudio A; Marucci A; Cantatore FP
    J Rheumatol; 2013 May; 40(5):684-94. PubMed ID: 23457386
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of Wnt/β-catenin and RANKL/OPG in bone healing of diabetic Charcot arthropathy patients.
    Folestad A; Ålund M; Asteberg S; Fowelin J; Aurell Y; Göthlin J; Cassuto J
    Acta Orthop; 2015; 86(4):415-25. PubMed ID: 25811776
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of zoledronic acid on serum dickkopf-1, osteoprotegerin, and RANKL in patients with Paget's disease of bone.
    Polyzos SA; Anastasilakis AD; Efstathiadou Z; Kita M; Litsas I; Avramidis A; Arsos G; Moralidis E; Gerou S; Pavlidou V; Papatheodorou A; Terpos E
    Horm Metab Res; 2009 Nov; 41(11):846-50. PubMed ID: 19670154
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of the Effect of Methotrexate Therapy on Bone Metabolism in Patients with Rheumatoid Arthritis.
    Świerkot J; Gruszecka K; Matuszewska A; Wiland P
    Arch Immunol Ther Exp (Warsz); 2015 Oct; 63(5):397-404. PubMed ID: 25837853
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Higher levels of s-RANKL and osteoprotegerin in children and adolescents with type 1 diabetes mellitus may indicate increased osteoclast signaling and predisposition to lower bone mass: a multivariate cross-sectional analysis.
    Tsentidis C; Gourgiotis D; Kossiva L; Doulgeraki A; Marmarinos A; Galli-Tsinopoulou A; Karavanaki K
    Osteoporos Int; 2016 Apr; 27(4):1631-1643. PubMed ID: 26588909
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum levels of the bone turnover markers dickkopf-1, sclerostin, osteoprotegerin, osteopontin, osteocalcin and 25-hydroxyvitamin D in Swedish geriatric patients aged 75 years or older with a fresh hip fracture and in healthy controls.
    Wanby P; Nobin R; Von SP; Brudin L; Carlsson M
    J Endocrinol Invest; 2016 Aug; 39(8):855-63. PubMed ID: 26850415
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of Serum sRANKL, sRANKL/OPG Ratio, and Other Bone Turnover Markers with the Estimated 10-Year Risk of Major and Hip Osteoporotic Fractures in Rheumatoid Arthritis: A Cross-Sectional Study.
    Nava-Valdivia CA; Ponce-Guarneros JM; Saldaña-Cruz AM; Corona-Sanchez EG; Ramirez-Villafaña M; Perez-Guerrero EE; Murillo-Saich JD; Contreras-Haro B; Vazquez-Villegas ML; Gonzalez-Ponce F; Bonilla-Lara D; Jacobo-Cuevas H; Centeno-Valadez JD; Echeverria-Gonzalez G; Cerpa-Cruz S; Alcaraz-Lopez MF; Cardona-Muñoz EG; Salazar-Paramo M; Gonzalez-Lopez L; Gamez-Nava JI
    Biomed Res Int; 2021; 2021():5567666. PubMed ID: 34497849
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pulsed electromagnetic fields modulate bone metabolism via RANKL/OPG and Wnt/β-catenin pathways in women with postmenopausal osteoporosis: A pilot study.
    Catalano A; Loddo S; Bellone F; Pecora C; Lasco A; Morabito N
    Bone; 2018 Nov; 116():42-46. PubMed ID: 30010081
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Osteoprotegerin and RANKL in the pathogenesis of thalassemia-induced osteoporosis: new pieces of the puzzle.
    Morabito N; Gaudio A; Lasco A; Atteritano M; Pizzoleo MA; Cincotta M; La Rosa M; Guarino R; Meo A; Frisina N
    J Bone Miner Res; 2004 May; 19(5):722-7. PubMed ID: 15068494
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum osteoprotegerin, RANKL, and Dkk-1 levels in adults with Langerhans cell histiocytosis.
    Makras P; Polyzos SA; Anastasilakis AD; Terpos E; Kanakis G; Schini M; Papatheodorou A; Kaltsas GA
    J Clin Endocrinol Metab; 2012 Apr; 97(4):E618-21. PubMed ID: 22278426
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of recent spinal cord injury on the OPG/RANKL system and its relationship with bone loss and the response to denosumab therapy.
    Gifre L; Ruiz-Gaspà S; Carrasco JL; Portell E; Vidal J; Muxi A; Monegal A; Guañabens N; Peris P
    Osteoporos Int; 2017 Sep; 28(9):2707-2715. PubMed ID: 28580511
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum RANKL, osteoprotegerin (OPG) and RANKL/OPG ratio in children with systemic lupus erythematosus.
    Ali R; Hammad A; El-Nahrery E; Hamdy N; Elhawary AK; Eid R
    Lupus; 2019 Sep; 28(10):1233-1242. PubMed ID: 31403902
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Osteoprotegerin and RANKL in the pathogenesis of osteoporosis in patients with thalassaemia major.
    Pietrapertosa AC; Minenna G; Colella SM; Santeramo TM; Renni R; D'Amore M
    Panminerva Med; 2009 Mar; 51(1):17-23. PubMed ID: 19352306
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum osteoprotegerin and RANKL levels in chronic alcoholic liver disease.
    García-Valdecasas-Campelo E; González-Reimers E; Santolaria-Fernández F; De la Vega-Prieto MJ; Milena-Abril A; Sánchez-Pérez MJ; Martínez-Riera A; Gómez-Rodríguez Mde L
    Alcohol Alcohol; 2006; 41(3):261-6. PubMed ID: 16476762
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circulating osteoprotegerin and receptor activator of NF-kappaB ligand system in patients with beta-thalassemia major.
    Angelopoulos NG; Goula A; Katounda E; Rombopoulos G; Kaltzidou V; Kaltsas D; Malaktari S; Athanasiou V; Tolis G
    J Bone Miner Metab; 2007; 25(1):60-7. PubMed ID: 17187195
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of dried plum on serum levels of receptor activator of NF-κB ligand, osteoprotegerin and sclerostin in osteopenic postmenopausal women: a randomised controlled trial.
    Hooshmand S; Brisco JR; Arjmandi BH
    Br J Nutr; 2014 Jul; 112(1):55-60. PubMed ID: 24780728
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Role of Serum Expression Levels of Microrna-21 on Bone Mineral Density in Hypostrogenic Postmenopausal Women with Osteoporosis: Study on Level of RANKL, OPG, TGFβ-1, Sclerostin, RANKL/OPG Ratio, and Physical Activity.
    Suarjana IN; Isbagio H; Soewondo P; Rachman IA; Sadikin M; Prihartono J; Malik SG; Soeroso J
    Acta Med Indones; 2019 Jul; 51(3):245-252. PubMed ID: 31699948
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.